Exploration of Targeted Anti-tumor Therapy,
Год журнала:
2024,
Номер
5(4), С. 971 - 980
Опубликована: Июль 29, 2024
The
landscape
of
treatment
for
first-line
therapy
in
advanced
urothelial
cancer
(aUC)
and
metastatic
(mUC)
has
rapidly
changed
the
last
year
alone.
Maintenance
avelumab
remains
a
viable
option
many
patients
across
globe
those
who
have
responded
or
achieved
stable
disease
after
platinum-based
chemotherapy.
However,
recent
FDA
approvals
based
on
EV-302
enfortumab
vedotin
(EV)
pembrolizumab,
as
well
CheckMate-904
with
gemcitabine
cisplatin
nivolumab
(GC+N)
followed
by
maintenance
left
clinicians
complicated
decision
determining
which
regimen
is
most
appropriate
their
individual
untreated
aUC.
This
commentary
highlights
key
trials
that
set
standard-of-care
front-line
aUC
suggestions
choosing
different
regimens
patient.
Cellular and Molecular Immunology,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 10, 2024
While
immunotherapy
with
immune
checkpoint
inhibitors
(ICIs)
has
revolutionized
the
clinical
management
of
various
malignancies,
a
large
fraction
patients
are
refractory
to
ICIs
employed
as
standalone
therapeutics,
necessitating
development
combinatorial
treatment
strategies.
Immunogenic
cell
death
(ICD)
inducers
have
attracted
considerable
interest
partners
for
ICIs,
at
least
in
part
owing
their
ability
initiate
tumor-targeting
adaptive
response.
However,
compared
either
approach
alone,
regimens
involving
ICD
and
not
always
shown
superior
activity.
Here,
we
discuss
accumulating
evidence
on
therapeutic
interactions
between
oncological
settings,
identify
key
factors
that
may
explain
discrepancies
preclinical
findings,
propose
strategies
address
existing
challenges
increase
efficacy
these
combinations
cancer.
World Journal of Surgical Oncology,
Год журнала:
2025,
Номер
23(1)
Опубликована: Апрель 9, 2025
There
is
still
controversy
regarding
the
safety
and
efficacy
of
atezolizumab
for
treatment
urothelial
carcinoma
(UC).
This
research
aimed
to
extensively
investigate
effectiveness
as
a
therapy
UC.
A
thorough
literature
review
was
conducted
using
databases
including
PubMed,
Embase,
Cochrane
Library,
Web
Science.
The
search
included
studies
published
from
inception
each
database
until
May
24,
2024.
primary
outcomes,
progression-free
survival
(PFS)
overall
(OS),
were
calculated
hazard
ratios
(HRs)
their
corresponding
95%
confidence
intervals
(CIs).
Ten
randomized
controlled
trials
(RCTs)
totaling
4,148
participants
in
our
analysis.
Compared
UC
patients
who
received
placebo,
either
alone
or
combination
with
chemotherapy
medications,
aggregated
data
showed
that
had
significantly
longer
OS(HR
=
0.88,
CI
[0.83,
0.94],
p
<
0.0001).
Three
RCTs
also
provided
on
PFS,
showing
atezolizumab,
addition
instead
chemotherapy,
PFS
than
those
placebo
without
(HR
0.85,
[0.76,
0.95],
0.004).
Atezolizumab
has
demonstrated
significant
improvements
OS
among
UC,
offering
crucial
insights
decision-making
immunotherapy.
https://www.crd.york.ac.uk/PROSPERO/#recordDetails
,
identifier
[CRD42024556757].
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(12), С. 6750 - 6750
Опубликована: Июнь 19, 2024
The
management
of
advanced
bladder
carcinoma
involves
a
multidisciplinary
approach,
but
the
prognosis
remains
poor
for
many
patients.
immune
system
plays
crucial
role
in
this
disease,
influencing
both
tumor
development
and
response
to
treatment,
exploiting
against
can
be
valuable
strategy
destroy
neoplastic
cells.
This
is
biological
principle
underlying
Bacillus
Calmette-Guérin
(BCG)
use
and,
more
recently,
checkpoint
inhibitors
(ICIs),
like
PD-1
(programmed
death-1)/PD-L1
death-ligand
1)
inhibitors.
In
fact,
one
best
studied
checkpoints
represented
by
PD-1/PD-L1
axis,
which
well-known
escape
adopted
PD-L1
expression
has
been
associated
with
higher
pathologic
stage
shown
prognostic
value
carcinoma.
Interestingly,
high-grade
cancers
tend
express
levels
PD-L1,
suggesting
potential
such
an
axis
mediating
disease
progression.
Immunotherapy
therefore
emerged
as
treatment
option
efficacy
cancer
patients,
high
better
responses.
Our
review
aims
provide
comprehensive
overview
cancer,
focusing
on
its
implications
decisions
prediction
response.
Overall,
our
work
contribute
understanding
predictive
biomarker
highlight
shaping
therapeutic
approaches
cancer.
The Oncologist,
Год журнала:
2024,
Номер
29(12), С. 1003 - 1013
Опубликована: Авг. 21, 2024
Platinum-based
chemotherapy
has
been
the
standard
first-line
(1L)
treatment
for
advanced
urothelial
carcinoma
(UC)
decades,
based
on
proven
efficacy
and
established
safety
profiles
of
cisplatin-
carboplatin-based
regimens.
With
emergence
novel
regimens,
it
is
important
to
reevaluate
contextualize
role
1L
platinum-based
chemotherapy.
followed
by
avelumab
maintenance
in
patients
without
disease
progression
following
was
as
a
regimen
JAVELIN
Bladder
100
phase
III
trial.
More
recently,
EV-302
trial
showed
superiority
enfortumab
vedotin
(EV)
+
pembrolizumab
versus
chemotherapy,
Checkmate
901
nivolumab
cisplatin/gemcitabine
alone.
These
2
regimens
have
now
included
options
guidelines
UC.
EV
preferred
treatment,
locations
where
not
available
or
individual
are
considered
suitable,
recommended
cisplatin-based
In
this
review,
we
discuss
current
UC
guidelines,
practical
considerations
with
maintenance,
recent
trials
cisplatin/gemcitabine,
treatments,
second-line
options.
Cancers,
Год журнала:
2024,
Номер
16(9), С. 1780 - 1780
Опубликована: Май 5, 2024
In
the
past
decade,
therapeutic
arsenal
for
metastatic
bladder
cancer
has
expanded
considerably,
with
development
of
immune
checkpoint
inhibitors
(ICIs),
antibody-drug
conjugates
such
as
enfortumab
vedotin,
and
anti-fibroblast
growth
factor
receptor
agents.
Clinical
trials
evaluating
ICIs
neoadjuvants,
adjuvants,
or
first-
second-line
treatments
have
produced
conflicting
results.
However,
first-line
strategies
been
redefined
by
recent
publication
results
from
two
clinical
trials:
CheckMate-901,
which
demonstrated
superiority
combined
treatment
nivolumab
chemotherapy
in
extending
overall
survival,
EV-302,
that
pembrolizumab
vedotin
reduced
risk
death
53%.
this
review,
we
discuss
role
ICIs,
alone
combination,
management
adjuvant
settings
2024,
considering
latest
published
trials.
The
potential
neoadjuvants
is
also
discussed.
